Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in CD79B Mutant Relapsed/Refractory DLBCL
NCT05068440Phase 2Completed
- Sponsor
- BeiGene
- Start
- Aug 2021
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by BeiGene. Started Aug 2021; status: completed.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05068440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068440.